Doxycyline
ApprovedSmall molecule
Doxycyline is one of 9 small molecule programs targeting Cicatricial Alopecia. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Cicatricial Alopecia
#DrugCompanyPhaseTrials
1Rogaine
PfizerApproved
Otezla
AmgenApproved
Opzelura
PfizerApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Anzupgo
Alnylam PharmaceuticalsPhase 2
PF-06700841
PfizerPhase 2
PF-06651600
PfizerPhase 2
Doxycyline
WWake Forest University Health Sciences
Approved
Calcipotriol
LEO PharmaPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Doxycyline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details